Y. Hei

1.0k total citations
20 papers, 800 citations indexed

About

Y. Hei is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Y. Hei has authored 20 papers receiving a total of 800 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Y. Hei's work include Lung Cancer Treatments and Mutations (9 papers), Bone health and treatments (8 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Y. Hei is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Bone health and treatments (8 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Y. Hei collaborates with scholars based in United States, Canada and India. Y. Hei's co-authors include Allan Lipton, Pierre Major, Richard J. Cook, Robert E. Coleman, J. E. Brown, Ming Zheng, Ker‐Ai Lee, Matthew Smith, Jesse McGreivy and Elwyn Loh and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

Y. Hei

19 papers receiving 786 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Y. Hei United States 9 634 335 261 213 118 20 800
Armando Orlandi Italy 17 519 0.8× 248 0.7× 100 0.4× 192 0.9× 124 1.1× 90 879
Francesca Mazzoni Italy 18 568 0.9× 470 1.4× 63 0.2× 178 0.8× 67 0.6× 63 821
Sue Chua United Kingdom 14 285 0.4× 390 1.2× 424 1.6× 78 0.4× 62 0.5× 27 714
Zafeiris Zafeiriou United Kingdom 13 422 0.7× 536 1.6× 172 0.7× 158 0.7× 43 0.4× 31 873
D. Ilegbodu United States 12 574 0.9× 181 0.5× 155 0.6× 105 0.5× 18 0.2× 30 711
Ryan D. Stephenson United States 9 281 0.4× 370 1.1× 185 0.7× 103 0.5× 52 0.4× 18 539
Yunjiang Liu China 13 517 0.8× 235 0.7× 154 0.6× 186 0.9× 123 1.0× 57 813
C. Hudis United States 13 632 1.0× 100 0.3× 186 0.7× 214 1.0× 27 0.2× 59 801
R. Nevin Murray Canada 7 203 0.3× 540 1.6× 242 0.9× 99 0.5× 29 0.2× 10 651
Janice F. Eakle United States 9 565 0.9× 345 1.0× 45 0.2× 246 1.2× 60 0.5× 22 805

Countries citing papers authored by Y. Hei

Since Specialization
Citations

This map shows the geographic impact of Y. Hei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Hei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Hei more than expected).

Fields of papers citing papers by Y. Hei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Hei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Hei. The network helps show where Y. Hei may publish in the future.

Co-authorship network of co-authors of Y. Hei

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Hei. A scholar is included among the top collaborators of Y. Hei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Hei. Y. Hei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kubota, Kaoru, Y. Ichinose, Giorgio V. Scagliotti, et al.. (2014). Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Annals of Oncology. 25(2). 529–536. 20 indexed citations
3.
Claret, Laurent, et al.. (2012). Simulations Using a Drug–Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non–Small-Cell Lung Cancer. Clinical Pharmacology & Therapeutics. 92(5). 631–634. 29 indexed citations
4.
Kindler, Hedy L., Donald Richards, Lawrence Garbo, et al.. (2012). A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology. 23(11). 2834–2842. 157 indexed citations
5.
Blumenschein, George R., Fairooz F. Kabbinavar, Hari Menon, et al.. (2011). A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Annals of Oncology. 22(9). 2057–2067. 77 indexed citations
6.
Tebbutt, N. C., Lara Lipton, Ralph V. Boccia, et al.. (2011). The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). e13555–e13555. 3 indexed citations
7.
Paz‐Ares, Luis, Beatrix Bálint, Jan P. van Meerbeeck, et al.. (2010). A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) +/- CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC). Annals of Oncology. 21. 2 indexed citations
8.
9.
10.
11.
Blackhall, Fiona, Petr Zatloukal, István Albert, et al.. (2010). A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7534–7534. 8 indexed citations
12.
Cetin, Karynsa, David S. Ettinger, Y. Hei, & C. D. O’Malley. (2009). Prognostic factors by histologic subtype in stage IV non-small cell lung cancer (NSCLC): A population-based survival analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988–2003). Journal of Clinical Oncology. 27(15_suppl). 11053–11053. 1 indexed citations
13.
Matczak, Ewa, Vera Hirsh, Allan Lipton, et al.. (2006). Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP). Journal of Clinical Oncology. 24(18_suppl). 7228–7228. 8 indexed citations
14.
Brown, J. E., Richard J. Cook, Pierre Major, et al.. (2005). Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. JNCI Journal of the National Cancer Institute. 97(1). 59–69. 432 indexed citations
15.
Smith, Matthew Ryan, Fairooz F. Kabbinavar, Fred Saad, et al.. (2005). Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 4514–4514. 1 indexed citations
16.
Lipton, Allan, Y. Hei, RE Coleman, Pierre Major, & Richard J. Cook. (2005). Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. Journal of Clinical Oncology. 23(16_suppl). 532–532. 7 indexed citations
17.
Kaminski, Mary, Lee S. Rosen, David Gordon, Min Zheng, & Y. Hei. (2004). Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. Journal of Clinical Oncology. 22(14_suppl). 857–857. 12 indexed citations
18.
Hirsh, Vera, N. Simon Tchekmedyian, Lee S. Rosen, Min Zheng, & Y. Hei. (2004). Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications. Journal of Clinical Oncology. 22(14_suppl). 7226–7226. 27 indexed citations
19.
Hirsh, Vera, et al.. (2004). Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications. Journal of Clinical Oncology. 22(14_suppl). 7226–7226. 1 indexed citations
20.
Kaminski, Mary, Lee S. Rosen, David Gordon, Min Zheng, & Y. Hei. (2004). Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. Journal of Clinical Oncology. 22(14_suppl). 857–857. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Armando Orlandi Breakdown of academic impact, for papers by Francesca Mazzoni Breakdown of academic impact, for papers by Sue Chua Breakdown of academic impact, for papers by Zafeiris Zafeiriou Breakdown of academic impact, for papers by D. Ilegbodu Breakdown of academic impact, for papers by Ryan D. Stephenson Breakdown of academic impact, for papers by Yunjiang Liu Breakdown of academic impact, for papers by C. Hudis Breakdown of academic impact, for papers by R. Nevin Murray Breakdown of academic impact, for papers by Janice F. Eakle
Rankless by CCL
2026